When comparing GLP-1 side effects, it helps to separate any reported symptom from adverse events that led participants to stop treatment. This review pooled four randomized trials of injected semaglutide [1].
Weight loss and stopping treatment
The trials included 3,613 adults with overweight or obesity without type 2 diabetes. The pooled difference in weight change was 11.85 percentage points in favor of semaglutide (95% CI 10.90 to 12.81 points) [1].
Discontinuation due to adverse events was more frequent on semaglutide (risk ratio 2.62, 95% CI 1.70 to 4.03). Digestive events included nausea, vomiting, diarrhea and constipation. The review's Table 5 shows the event counts for each trial.
How the trial result applies to routine care
Studies of GLP-1 persistence in routine care also capture reasons such as cost and access. The trial estimate isolates discontinuations attributed to adverse events.
A relative risk compares groups and cannot predict an individual's chance of stopping. The trials also differ in how they enrolled participants and followed them.